High Lp(a): A Rising Risk Factor for Heart Disease & What It Means for Patients

The landscape of cardiovascular risk assessment is shifting, with increasing attention focused on lipoprotein(a) [Lp(a)], a genetically determined fat-carrying particle in the blood. Recent guidance emphasizes earlier preventative measures for individuals with elevated Lp(a) levels, yet a significant gap remains between identifying these patients and initiating appropriate interventions. This disconnect highlights a challenge in translating scientific advancements into consistent clinical practice.

Understanding Lipoprotein(a) and Cardiovascular Risk

Lipoprotein(a) is distinct from LDL-cholesterol, often referred to as “bad” cholesterol, though both contribute to the risk of atherosclerotic cardiovascular disease (ASCVD) – a condition where plaque builds up inside the arteries. Unlike LDL-cholesterol, Lp(a) levels are largely determined by genetics, meaning lifestyle changes have a limited impact on reducing them. Elevated levels, defined as greater than 50 mg/dL, affect an estimated 20–30% of the global population. The higher the Lp(a) level, the greater the risk of heart attack, stroke, and aortic valve stenosis.

For years, Lp(a) was underappreciated in routine cardiovascular risk assessment. However, its strong, independent association with ASCVD, coupled with the development of targeted therapies, has spurred renewed interest. The 2026 ACC/AHA/Multisociety Dyslipidemia Guideline, released earlier this month, reflects this shift, advocating for universal lipid testing and management of dyslipidemia throughout life. The National Lipid Association details the guideline’s release, emphasizing a comprehensive approach to lipid management.

Latest Guidance and the Focus on Early Intervention

The updated guideline, published in the Journal of the American College of Cardiology (JACC) and Circulation, consolidates evidence-based recommendations for managing dyslipidemias, effectively replacing the 2018 guidelines. The American College of Cardiology provides details on the new guideline, highlighting a major focus on earlier intervention, even in childhood.

Specifically, the guideline suggests considering pharmacotherapy – medication – in young people with familial hypercholesterolemia (FH) or those with exceptionally high LDL-cholesterol levels (≥160 mg/dL) or a strong family history of premature ASCVD. For adults, the guideline recommends using the newer PREVENT-ASCVD equations, rather than older risk assessment tools, to guide lipid-lowering therapy. This shift aims to identify individuals at risk earlier and initiate treatment before significant arterial damage occurs.

The Clinician Response Gap

Despite the updated guidance and growing awareness of Lp(a)’s significance, a critical challenge persists: clinicians are not consistently responding to elevated Lp(a) levels, particularly when those levels don’t immediately trigger guideline-directed treatment. In other words that many individuals with a genetically elevated risk may not be receiving the preventative care they need. The reasons for this gap are complex and likely multifactorial. They may include a lack of familiarity with Lp(a) testing and interpretation, uncertainty about optimal treatment strategies (given the relatively recent development of targeted therapies), and challenges integrating Lp(a) assessment into routine clinical workflows.

What Does This Mean for Patients?

For individuals concerned about their cardiovascular risk, understanding Lp(a) is becoming increasingly important. While a simple cholesterol panel doesn’t typically include Lp(a) measurement, it can be specifically requested by a healthcare provider. However, it’s crucial to remember that Lp(a) is just one piece of the puzzle. A comprehensive cardiovascular risk assessment should also consider traditional risk factors like age, blood pressure, smoking status, family history, and other lipid levels.

It’s also important to understand the limitations of Lp(a) testing. Currently, there is some variability in Lp(a) measurement between different laboratories, and the optimal Lp(a) target level remains a subject of ongoing research. The American Heart Association’s newsroom emphasizes the guideline’s focus on lowering LDL-C goals and reducing lifetime exposure to unhealthy lipids.

The Role of Emerging Therapies

The increased focus on Lp(a) is partly driven by the development of new therapies specifically designed to lower its levels. While statins, the mainstay of cholesterol-lowering treatment, have a limited effect on Lp(a), other drugs, such as antisense oligonucleotides (ASOs), are showing promise in clinical trials. These ASOs work by blocking the production of Lp(a) in the liver. However, these therapies are still relatively new and are not yet widely available. Further research is needed to determine their long-term efficacy and safety.

Trial Endpoints and Uncertainty

Clinical trials evaluating Lp(a)-lowering therapies are ongoing, and their results will be crucial in refining treatment strategies. Key endpoints in these trials include major adverse cardiovascular events (MACE), such as heart attack, stroke, and cardiovascular death. However, it’s important to note that these trials often have limitations, such as relatively small sample sizes and varying patient populations. The results should be interpreted cautiously.

What Comes Next: Surveillance and Guideline Updates

The evolving understanding of Lp(a) and its impact on cardiovascular health will likely lead to further refinements in clinical guidelines and treatment recommendations. Ongoing surveillance of Lp(a) levels in large populations will assist to better define the prevalence of elevated levels and identify individuals at highest risk. Continued research into the genetic and molecular mechanisms underlying Lp(a) metabolism may lead to the development of even more effective therapies. The process of guideline updates is continuous, informed by new evidence and expert consensus, ensuring that clinical practice remains aligned with the latest scientific knowledge.